Revolutionary CAR-T Therapy Shows Promise for Autoimmune Disease Treatment
Key Insights
Scientists are developing revolutionary treatments for autoimmune diseases like lupus (search) and rheumatoid arthritis (search) by reprogramming patients' immune systems rather than just suppressing them.
CAR-T therapy (search), originally developed for blood cancers, has shown remarkable early results with one lupus (search) patient remaining in remission since March 2021 without additional medication.
Multiple experimental approaches including T cell engagers, regulatory T cells (search), and mRNA-based treatments are being tested to provide more precise and potentially curative therapies.
Scientists are pioneering a revolutionary approach to treating devastating autoimmune diseases like rheumatoid arthritis (search), multiple sclerosis (search), and lupus (search) by reprogramming patients' dysfunctional immune systems rather than simply suppressing them. This paradigm shift offers hope for millions of patients who currently face lifelong expensive medications with serious side effects and limited efficacy.
"We're entering a new era," said Dr. Maximilian Konig, a rheumatologist at Johns Hopkins University studying these novel treatments. They offer "the chance to control disease in a way we've never seen before."
CAR-T Therapy Breakthrough Shows Dramatic Results
The most advanced of these experimental treatments adapts CAR-T therapy (search), originally developed for hard-to-treat blood cancers, for autoimmune diseases. The approach targets B cells (search), which go awry in different ways in both cancer and autoimmune conditions.
The breakthrough began in Germany, where Dr. Georg Schett at the University of Erlangen-Nuremberg (search) treated a severely ill young woman with lupus (search) who had failed other treatments. After one CAR-T infusion, she has remained in remission with no other medicine since March 2021.
Last month, Schett reported to the American College of Rheumatology how his team gradually treated dozens more patients with additional diseases including myositis (search) and scleroderma (search), with few relapses observed so far. These early results were "shocking," Hopkins' Konig recalled, leading to an explosion of clinical trials testing CAR-T therapy (search) for autoimmune diseases worldwide.
The treatment process involves filtering immune soldiers called T cells (search) from a patient's blood and programming them in a laboratory to destroy their B cell relatives. After chemotherapy to eliminate additional immune cells, millions of copies of these "living drugs" are infused back into the patient.
Patient Success Stories Drive Research Forward
Mileydy Gonzalez, a 35-year-old New York resident, exemplifies the treatment's potential. Diagnosed with lupus (search) at 24, her disease was worsening and attacking her lungs and kidneys. She had trouble breathing, needed help to stand and walk, and couldn't pick up her 3-year-old son when her doctor at NYU Langone Health suggested the experimental CAR-T study last July.
"I'm going to trust you," Gonzalez decided, despite never having heard of the therapy. Over several months, she slowly regained energy and strength. "I can actually run, I can chase my kid," said Gonzalez, who is now pain- and pill-free. "I had forgotten what it was to be me."
Similarly, Allie Rubin, 60, of Boca Raton, Florida, spent three decades battling lupus (search), including scary hospitalizations when it attacked her spinal cord. She qualified for CAR-T when she also developed lymphoma. Despite a serious side effect that delayed recovery, next month will mark two years without signs of either cancer or lupus. "I just remember I woke up one day and thought, 'Oh my god, I don't feel sick anymore,'" she said.
Multiple Innovative Approaches Under Development
Beyond CAR-T therapy (search), researchers are exploring several complementary strategies. One approach uses "peacekeeper" cells central to this year's Nobel Prize. Regulatory T cells (search), a rare subset that tamp down inflammation and help control cells that mistakenly attack healthy tissue, are being engineered by biotech companies to calm autoimmune reactions rather than attack like CAR-T does.
Scientists are also repurposing T cell engagers, cancer drugs that don't require custom engineering. These lab-made antibodies act as matchmakers, redirecting existing T cells (search) to target antibody-producing B cells (search). Dr. Ricardo Grieshaber-Bouyer, working with Schett, reported giving teclistamab to 10 patients with various diseases including Sjögren's (search), myositis (search), and systemic sclerosis (search). All but one improved significantly, and six achieved drug-free remission.
Hopkins' Konig aims for even greater precision, targeting "only that very small population of rogue cells that really causes the damage." His lab is engineering T cell engagers that would mark only "bad" B cells (search) for destruction while leaving healthy ones to fight infection.
mRNA Technology Offers Future Promise
In another Hopkins laboratory, biomedical engineer Jordan Green is developing a method for the immune system to reprogram itself using messenger RNA instructions, similar to the genetic code used in COVID-19 vaccines. His team packages mRNA in biodegradable nanoparticles that can be injected like a drug to instruct immune "generals" to curb bad T cells (search) and deploy more peacemaker cells.
Green's research focuses on Type 1 diabetes (search), where computer screens in his lab display biological maps showing insulin-producing pancreatic cells. Red marks indicate rogue T cells (search) destroying insulin production, while yellow shows outnumbered regulatory T cells (search). The goal is to shift this balance through mRNA instructions that would cause healthy cells to "divide, divide, divide and make a whole army of healthy cells that then help treat the disease," Green explained.
Prevention Strategies Show Early Promise
A drug for Type 1 diabetes (search) "is forging the path," said Dr. Kevin Deane at the University of Colorado Anschutz (search). The drug teplizumab is approved to delay first symptoms by modulating rogue T cells (search) and prolonging insulin production in people identified through blood tests as developing the disease.
Deane studies rheumatoid arthritis (search) and hopes to find similar preventive approaches. About 30% of people with certain self-reactive antibodies will eventually develop RA. A new study tracked some of these individuals for seven years, mapping immune changes leading to disease long before joints become swollen or painful. These changes represent potential drug targets, and Deane is leading the StopRA: National study to identify and learn from more at-risk people.
Challenges and Future Outlook
While promising, these treatments face significant challenges. CAR-T therapy (search) is grueling, time-consuming, and costly, with cancer treatments costing $500,000 due to customization requirements. Some companies are testing off-the-shelf versions made from healthy donor cells to address these limitations.
Questions remain about CAR-T's safety and duration of effects, though it is furthest along in testing among the experimental approaches. Studies in people for mRNA-based treatments are still several years away.
Despite these challenges, researchers remain optimistic about the field's trajectory. "We've never been closer to getting to — and we don't like to say it — a potential cure," said Hopkins' Konig. "I think the next 10 years will dramatically change our field forever."